SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

ESMO Open · 2021 · PMC8134736 · PMID 33984672

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

did not reach statistical significanceP = 0.056so close (0.05 < p ≤ 0.1)

OS by previous therapy Prior cisplatin-based chemotherapy was associated with a numerically longer median OS compared with carboplatin-based chemotherapy [9.4 months (95% CI: 8.1-10.9) versus 7.5 months (95% CI: 6.4-9.2)] but the difference did not reach statistical significance ( P = 0.056; Figure 1 B, Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.